Medicine and Dentistry
Pediatrics
91%
Airway Smooth Muscle
88%
Airway Smooth Muscle Cell
80%
Clinical Trial
52%
Asthma
47%
Cell Proliferation
34%
Extubation
34%
Airway Resistance
27%
Phosphatase
26%
Cytoskeleton
26%
Pediatrics Patient
22%
Smooth Muscle
21%
Lung
21%
Actin
20%
Silo-Filler's Disease
20%
Intensive Care
20%
Continuous Positive Airway Pressure
19%
Y-27632
19%
Breathing
18%
Exhalation
18%
Myosin
17%
Thermal Burn
17%
Methacholine
17%
Oxygen Consumption
17%
Cystic Fibrosis
17%
Clonidine
17%
Drug Therapy
17%
Isotopes of Calcium
17%
Pulmonary Hemorrhage
17%
Respiratory System
17%
Lung Mechanics
17%
Ventilator Weaning
17%
Airway Obstruction
17%
Muscle Contractility
17%
Focal Adhesion
17%
Opiate
17%
Cell Strain
17%
Disease Severity
17%
Messenger RNA
17%
Morphine
15%
Health Outcomes
15%
Cell Membrane
12%
Bleeding
11%
Rho Kinase Inhibitor
10%
Smooth Muscle Contractility
10%
Child Health
10%
Environmental Influence
10%
Placebo
9%
Contractile Protein
9%
Cytometry
8%
Immunology and Microbiology
Airway Smooth Muscle Cell
100%
Smooth Muscle
91%
Asthma
39%
Cell Proliferation
34%
Lower Respiratory Tract
34%
Mechanical Stress
32%
Actin
29%
Rigidity
26%
Arm
22%
Muscle Contractility
20%
Drug Megadose
20%
Lymphocyte Count
17%
Actin Filament
17%
CD4
17%
Cytoskeleton
17%
Nomenclature
17%
Focal Adhesion
17%
Steady State
17%
Microfilament
17%
Blood Transfusion
17%
T Cell
17%
Dynamics
17%
Allele
17%
Leporidae
17%
Terbutaline
17%
Glucocorticoid
17%
Exhalation
17%
Lung Function
10%
Agonist
10%
Stress Fiber
9%
Tidal Volume
8%
Pharmacokinetics
8%
Asthmatic State
8%
Smooth Muscle Contractility
8%
Airway Pressure
8%
Airflow
8%
Hyperoxia
8%
Clostridium Botulinum Type A
8%
CD3 Antigen
8%
Cell Membrane
7%
Light Chain
7%
Blood Pressure
6%
Transmission Electron Microscopy
6%
Protein Content
6%
Normal Human
5%
Aminophylline
5%
Pharmacology, Toxicology and Pharmaceutical Science
Asthma
93%
Actin
34%
Prospective Study
34%
Clinical Trial
34%
Terbutaline
34%
Pharmacokinetics
34%
Phosphatase
26%
Burn
24%
Lower Respiratory Tract Infection
23%
Cohort Study
19%
Myosin Light Chain
19%
4 (1 Aminoethyl) N (4 Pyridyl)cyclohexanecarboxamide
18%
Tolerability
17%
Lung Hemorrhage
17%
Withdrawal Syndrome
17%
Clonidine
17%
Phenobarbital
17%
Paxillin
17%
Airway Obstruction
17%
Green Fluorescent Protein
17%
Opiate
17%
Metronidazole
17%
Asthmatic State
17%
Respiratory Tract Infection
17%
Morphine
15%
Bleeding
11%
Talin
11%
Placebo
9%
Contractile Protein
9%
Rho Kinase Inhibitor
9%
Heat Shock Protein 27
8%
Myosin
8%
Lysophosphatidic Acid
8%
Isoprenaline
8%
RhoA Guanine Nucleotide Binding Protein
8%
Myosin Light Chain Kinase
8%
Muscle Rigidity
8%
Bronchiolitis
8%
Controlled Clinical Trial
8%
Clostridium Botulinum Type A
8%
Chimeric Protein
8%
Respiratory Failure
6%
Health Disparity
6%
Lung Dysplasia
6%
Hemoglobinuria
5%
Normal Human
5%
Adult Respiratory Distress Syndrome
5%
Herbimycin A
5%
Genistein
5%
Protein Tyrosine Kinase Inhibitor
5%
